ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3021% above fair value
$10.75+0.53 (+5.19%)
Close on Nov 13, 2026Market cap $97.63MP/E 53.8Yield –
ImmuCell cash
Cash and short-term investments held at the end of each period.
ImmuCell's cash was $7.91M at Sep 30, 2026. For fiscal 2025 it was $3.81M, up 1.3% from the year before. Over ten years it grew -4.5% a year on average. The highest annual figure on record is $10.62M in fiscal 2016.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.81M | +1.3% |
| FY2024 | Dec 31, 2024 | $3.76M | +284.0% |
| FY2023 | Dec 31, 2023 | $978.74K | -83.1% |
| FY2022 | Dec 31, 2022 | $5.79M | -43.1% |
| FY2021 | Dec 31, 2021 | $10.19M | +28.2% |
| FY2020 | Dec 31, 2020 | $7.95M | -9.4% |
| FY2019 | Dec 31, 2019 | $8.77M | +248.0% |
| FY2018 | Dec 31, 2018 | $2.52M | -33.6% |
| FY2017 | Dec 31, 2017 | $3.80M | -64.2% |
| FY2016 | Dec 31, 2016 | $10.62M | +75.8% |
| FY2015 | Dec 31, 2015 | $6.04M | +81.0% |
| FY2014 | Dec 31, 2014 | $3.34M | -36.5% |
| FY2013 | Dec 31, 2013 | $5.26M | +7.0% |
| FY2012 | Dec 31, 2012 | $4.91M | -0.9% |
| FY2011 | Dec 31, 2011 | $4.96M | +7.2% |
| FY2010 | Dec 31, 2010 | $4.63M | +374.2% |
| FY2009 | Dec 31, 2009 | $975.49K | -18.7% |
| FY2008 | Dec 31, 2008 | $1.20M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.91M | +103.7% |
| Q2 FY2026 | Jun 30, 2026 | $8.86M | +47.7% |
| Q1 FY2026 | Mar 31, 2026 | $6.81M | +48.1% |
| Q4 FY2025 | Dec 31, 2025 | $3.81M | +1.3% |
| Q3 FY2025 | Sep 30, 2025 | $3.89M | +2.0% |
| Q2 FY2025 | Jun 30, 2025 | $6.00M | +353.0% |
| Q1 FY2025 | Mar 31, 2025 | $4.60M | +378.9% |
| Q4 FY2024 | Dec 31, 2024 | $3.76M | +284.0% |
| Q3 FY2024 | Sep 30, 2024 | $3.81M | +91.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.32M | -8.9% |
| Q1 FY2024 | Mar 31, 2024 | $960.35K | -69.0% |
| Q4 FY2023 | Dec 31, 2023 | $978.74K | -83.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.99M | -77.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.45M | -86.8% |
| Q1 FY2023 | Mar 31, 2023 | $3.10M | -73.8% |
| Q4 FY2022 | Dec 31, 2022 | $5.79M | -43.1% |
| Q3 FY2022 | Sep 30, 2022 | $8.83M | -15.9% |
| Q2 FY2022 | Jun 30, 2022 | $11.04M | +3.2% |
| Q1 FY2022 | Mar 31, 2022 | $11.82M | +73.6% |
| Q4 FY2021 | Dec 31, 2021 | $10.19M | +28.2% |
| Q3 FY2021 | Sep 30, 2021 | $10.50M | +77.6% |
| Q2 FY2021 | Jun 30, 2021 | $10.70M | +30.6% |
| Q1 FY2021 | Mar 31, 2021 | $6.81M | -2.7% |
| Q4 FY2020 | Dec 31, 2020 | $7.95M | -9.4% |
| Q3 FY2020 | Sep 30, 2020 | $5.91M | -38.1% |
| Q2 FY2020 | Jun 30, 2020 | $8.19M | -17.8% |
| Q1 FY2020 | Mar 31, 2020 | $7.00M | -33.9% |
| Q4 FY2019 | Dec 31, 2019 | $8.77M | +248.0% |
| Q3 FY2019 | Sep 30, 2019 | $9.55M | +299.2% |
| Q2 FY2019 | Jun 30, 2019 | $9.97M | +296.6% |
| Q1 FY2019 | Mar 31, 2019 | $10.58M | +245.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.52M | -33.6% |
| Q3 FY2018 | Sep 30, 2018 | $2.39M | +3.8% |
| Q2 FY2018 | Jun 30, 2018 | $2.51M | -42.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.06M | -57.7% |
| Q4 FY2017 | Dec 31, 2017 | $3.80M | -64.2% |
| Q3 FY2017 | Sep 30, 2017 | $2.31M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.23M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.62M | – |
See a number that looks wrong?